This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Briguori, C. Articles by Ricciardelli, B. Search for Related Content PubMed PubMed Citation Articles by Briguori, C. Articles by Ricciardelli, B.

N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity

Carlo Briguori, MD, PhD^*,,*, Antonio Colombo, MD, Flavio Airoldi, MD, Anna Violante, MD^*, Alfredo Castelli, MD, Pasquale Balestrieri, MD^*, Pietro Paolo Elia, MD^*, Bruno Golia, MD^*, Stefano Lepore, MD^*, Guido Riviezzo, MD^*, Pierfranco Scarpato, MD^*, Mariateresa Librera, MD^*, Amelia Focaccio, MD^* and Bruno Ricciardelli, MD^*

^* Laboratory of Interventional Cardiology and Department of Cardiology, Clinica Mediterranea, Naples, Italy
Laboratory of Interventional Cardiology, "Vita e Salute" University School of Medicine, Milan, Italy

View larger version (10K): [in a new window]   Figure 1 Schematic representation of the distribution of the occurrence of contrast agent-associated nephrotoxicity in patients treated with the N-acetylcysteine (NAC group) and with fenoldopam mesylate (fenoldopam group). Filled areas = cases with event; open areas = cases without event.